Clinical trials. A pending subject

Analysis of the reasons for screening failure in phase I clinical trials in China: a retrospective study of the clinical trials screening process

“…In terms of the sex ratio, 1,133 males (69.1%) and 507 females (30.9%) were included, and among these subjects, 721 males (71.5%) and 287 females (28.5%) failed screening. In terms of ethnicity, a total of eight ethnic groups were noted: Hui [6], Tibetan [4], Manchu [3], Korean [1], Dai [1], Lahu [1], and Uygur [1]; the remainder were Han.…”

“…Considering China's large population and drug consumption market, multinational pharmaceutical companies have focused their attention on China, rendering it one of the world's most important clinical trial bases. However, the accumulation of many innovative drugs and generic drugs on the market puts tremendous pressure on the approval process, the institutions conducting the trials, and auxiliary organizations (e.g., CRO, SMO) (3,4). Between 2009 and 2018, the China National Medical Products Administration (NMPA) published a series of regulatory reform measures to overcome delays in drug approval, encourage innovation, and strengthen the standardization of drug research and development (5).…”

Updates in Hypertension Studies According to the Main Clinical Trials: A Review of the Past 45 Years about Pharmaceutical Intervention Effects

“…Since 1948, when the British epidemiologist Sir Austin Bradford Hill (1897–1991) demonstrated the causal relationship between habitual smoking and lung cancer, more than 150,000 randomized clinical trials have been carried out in different fields of health sciences, these being necessary for licensing the use of new drugs [ 6 ]. The most significant clinical trials began to take place in the 1980s; however, a large number of these trials were carried out in the first decade of this century.…”